Abstract
Stem cells exhibit simple and naive cellular features, yet their exact purpose for regenerative medicine continues to elude even the most elegantly designed research paradigms from developmental biology to clinical therapeutics. Based on their capacity to divide indefinitely and their dynamic differentiation into any type of tissue, the advent of transplantable stem cells has offered a potential treatment for aging-related and injury-mediated diseases. Recent laboratory evidence has demonstrated that transplanted human neural stem cells facilitate endogenous reparative mechanisms by initiating multiple regenerative processes in the brain neurogenic areas. Within these highly proliferative niches reside a myriad of potent regenerative molecules, including anti-inflammatory cytokines, proteomes, and neurotrophic factors, altogether representing a biochemical cocktail vital for restoring brain function in the aging and diseased brain. Here, we advance the concept of therapeutically repurposing stem cells not towards cell replacement per se, but rather exploiting the cells’ intrinsic properties to serve as the host brain regenerative catalysts.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- PD:
-
Parkinson’s Disease
- hNSCs:
-
human neural stem cells
- SVZ:
-
Subventricular zone
- SGZ:
-
Subgranular zone
- 6-OHDA:
-
6-hydroxydopamine
References
Acosta SA, Tajiri N, de la Pena I, Bastawrous M, Sanberg PR, Kaneko Y, Borlongan CV (2015a) Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson’s disease. J Cell Physiol 230(5):1024–1032
Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV (2015b) Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke 46(9):2616–2627
Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog Neurobiol 60(5):409–470
Bagetta V et al (2011) Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson’s disease. J Neurosci 31(35):12513–12522
Borlongan CV (2000) Transplantation therapy for Parkinson’s disease. Expert Opin Investig Drugs 9(10):2319–2330
Borlongan CV (2016a) Age of PISCES: stem-cell clinical trials in stroke. Lancet 388(10046):736–738
Borlongan CV (2016b) Preliminary reports of stereotaxic stem cell transplants in chronic stroke patients. Mol Ther 24(10):1710–1711
Borlongan CV, Sanberg PR, Freeman TB (1999) Neural transplantation for neurodegenerative disorders. Lancet 353(Suppl 1):SI29–SI30
Brundin P, Bjorklund A (1998) Survival of expanded dopaminergic precursors is critical for clinical trials. Nat Neurosci 1(7):537
Calabresi P, Castrioto A, Di Filippo M, Picconi B (2013) New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson’s disease. Lancet Neurol 12(8):811–821
Costa C et al (2012) Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease. Brain 135(Pt 6):1884–1899
Cox CS Jr et al (2011) Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery 68(3):588–600
Crowley MG, Liska MG, Borlongan CV (2017) Stem cell therapy for sequestering neuroinflammation in traumatic brain injury: an update on exosome-targeting to the spleen. J Neurosurg Sci 61(3):291–302
Dunnett SB, Bjorklund A, Lindvall O (2001) Cell therapy in Parkinson’s disease – stop or go? Nat Rev Neurosci 2(5):365–369
Freed CR et al (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Engl J Med 327(22):1549–1555
Freed CR et al (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344(10):710–719
Freeman TB et al (1995) Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson’s disease. Ann Neurol 38(3):379–388
Freeman TB et al (2000) Transplanted fetal striatum in Huntington’s disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 97(25):13877–13882
Hagell P et al (2002) Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 5(7):627–628
Hall H et al (2014) Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain 137(Pt 9):2493–2508
Herrera-Marschitz M, Arbuthnott G, Ungerstedt U (2010) The rotational model and microdialysis: significance for dopamine signalling, clinical studies, and beyond. Prog Neurobiol 90(2):176–189
Kalladka D et al (2016) Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 388(10046):787–796
Kefalopoulou Z et al (2014) Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71(1):83–87
Kitamura T et al (2017) Engrams and circuits crucial for systems consolidation of a memory. Science 356(6333):73–78
Kondziolka D et al (2000) Transplantation of cultured human neuronal cells for patients with stroke. Neurology 55(4):565–569
Kordower JH et al (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 332(17):1118–1124
Li W et al (2016) Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A 113(23):6544–6549
Lindvall O et al (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46(6):615–631
Lindvall O et al (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 247(4942):574–577
Lindvall O et al (1992) Transplantation of fetal dopamine neurons in Parkinson’s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 31(2):155–165
Napoli E, Borlongan CV (2016) Recent advances in stem cell-based therapeutics for stroke. Transl Stroke Res 7(6):452–457
Napoli E, Borlongan CV (2017a) Cell therapy in Parkinson’s disease: host brain repair machinery gets a boost from stem cell grafts. Stem Cells 35(6):1443–1445
Napoli E, Borlongan CV (2017b) Stem cell recipes of bone marrow and fish: just what the stroke doctors ordered. Stem Cell Rev 13(2):192–197
Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ (1979) Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204(4393):643–647
Redmond DE Jr et al (2007) Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A 104(29):12175–12180
Redondo RL, Kim J, Arons AL, Ramirez S, Liu X, Tonegawa S (2014) Bidirectional switch of the valence associated with a hippocampal contextual memory engram. Nature 513(7518):426–430
Tajiri N et al (2013) Stem cell recruitment of newly formed host cells via a successful seduction? Filling the gap between neurogenic niche and injured brain site. PLoS One 8(9):e74857
Tajiri N et al (2014a) Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats. J Neurosci 34(1):313–326
Tajiri N et al (2014b) Stem cell-paved biobridge facilitates neural repair in traumatic brain injury. Front Syst Neurosci 8:116
Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24(3):485–493
Ungerstedt U, Ljungberg T, Steg G (1974) Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 5:421–426
Wenning GK et al (1997) Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Ann Neurol 42(1):95–107
Yasuhara T et al (2006) Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J Neurosci 26(48):12497–12511
Zuo F, Xiong F, Wang X, Li X, Wang R, Ge W, Bao X (2017) Intrastriatal transplantation of human neural stem cells restores the impaired subventricular zone in parkinsonian mice. Stem Cells 35(6):1519–1531
Conflict of Interest Disclosure
CVB receives grant support from SanBio, Inc., Saneron CCEL Inc., Astellas Institute of Regenerative Medicine, International Stem Cell Corp., and royalties from Athersys, Inc.
Funding Source
CVB is funded by NIH R01NS071956, NIH R01 NS090962, NIH R21NS089851, NIH R21 NS094087, DOD W81XWH-11-1-0634, and VA Merit Review I01 BX001407.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Napoli, E., Lippert, T., Borlongan, C.V. (2018). Stem Cell Therapy: Repurposing Cell-Based Regenerative Medicine Beyond Cell Replacement. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 1. Advances in Experimental Medicine and Biology(), vol 1079. Springer, Cham. https://doi.org/10.1007/5584_2018_174
Download citation
DOI: https://doi.org/10.1007/5584_2018_174
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-93866-0
Online ISBN: 978-3-319-93867-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)